Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELEV Elevation Oncology	$0.38 +0.4%	$0.33	$0.22 ▼ $3.45	$22.61M	1.43	1.50 million shs	771,286 shs
ENLV Enlivex Therapeutics	$0.91 -3.7%	$0.96	$0.81 ▼ $1.76	$21.40M	0.74	127,327 shs	21,988 shs
GDTC CytoMed Therapeutics	$2.12 -0.8%	$2.30	$1.20 ▼ $4.05	$23.22M	-0.33	77,784 shs	577 shs
IMCC IM Cannabis	$2.44 -6.9%	$1.96	$1.29 ▼ $7.12	$5.45M	2.47	86,332 shs	37,598 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELEV Elevation Oncology	+0.18%	+24.61%	+8.94%	-28.64%	-88.68%
ENLV Enlivex Therapeutics	-0.21%	+2.17%	-6.00%	-22.95%	-32.37%
GDTC CytoMed Therapeutics	+0.47%	+3.85%	-6.17%	-14.11%	+2.40%
IMCC IM Cannabis	-0.76%	-8.07%	+74.67%	+47.19%	-8.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELEV Elevation Oncology	3.3897 of 5 stars	4.0	5.0	1.6	1.7	0.6
ENLV Enlivex Therapeutics	3.4548 of 5 stars	3.7	5.0	2.5	0.8	1.3
GDTC CytoMed Therapeutics	2.6169 of 5 stars	3.5	5.0	3.3	0.0	0.0
IMCC IM Cannabis	0.4075 of 5 stars	0.0	2.0	3.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELEV Elevation Oncology	2.00	Hold	$3.39	787.01% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	1,004.97% Upside
GDTC CytoMed Therapeutics	3.00	Buy	$5.00	135.63% Upside
IMCC IM Cannabis	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IMCC, ENLV, GDTC, and ELEV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/21/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/3/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
3/24/2025	ELEV Elevation Oncology	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$5.00 ➝ $1.00
3/24/2025	ENLV Enlivex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00
3/21/2025	ELEV Elevation Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
3/21/2025	ELEV Elevation Oncology	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$9.00 ➝ $1.00
3/21/2025	ELEV Elevation Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.29 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
GDTC CytoMed Therapeutics	$69.50K	334.02	N/A	N/A	$0.78 per share	2.72
IMCC IM Cannabis	$54.47M	0.10	N/A	N/A	$4.55 per share	0.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELEV Elevation Oncology	-$45.70M	-$0.82	N/A	N/A	N/A	N/A	-59.73%	-40.05%	8/5/2025 (Estimated)
ENLV Enlivex Therapeutics	-$29.07M	-$0.66	N/A	N/A	N/A	N/A	-67.57%	-58.45%	6/13/2025 (Estimated)
GDTC CytoMed Therapeutics	-$3.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/28/2025 (Estimated)
IMCC IM Cannabis	-$7.04M	-$0.64	N/A	N/A	N/A	-25.55%	-129.86%	-23.63%	8/12/2025 (Estimated)

Latest IMCC, ENLV, GDTC, and ELEV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/13/2025	Q4 2024	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
5/15/2025	Q1 2025	IMCC IM Cannabis	-$0.2540	$0.06	+$0.3140	$0.06	$11.45 million	$8.69 million
3/31/2025	Q4 2024	ENLV Enlivex Therapeutics	-$0.16	-$0.23	-$0.07	-$0.23	N/A	N/A
3/31/2025	Q4 2024	IMCC IM Cannabis	-$0.39	-$0.23	+$0.16	-$0.23	$14.48 million	$9.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
GDTC CytoMed Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELEV Elevation Oncology	0.45	17.77	17.77
ENLV Enlivex Therapeutics	N/A	9.71	9.71
GDTC CytoMed Therapeutics	0.04	21.54	N/A
IMCC IM Cannabis	0.10	0.70	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELEV Elevation Oncology	83.70%
ENLV Enlivex Therapeutics	1.02%
GDTC CytoMed Therapeutics	0.04%
IMCC IM Cannabis	7.68%

Insider Ownership

Company	Insider Ownership
ELEV Elevation Oncology	8.10%
ENLV Enlivex Therapeutics	12.28%
GDTC CytoMed Therapeutics	N/A
IMCC IM Cannabis	5.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELEV Elevation Oncology	40	59.22 million	54.33 million	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	18.78 million	Optionable
GDTC CytoMed Therapeutics	N/A	10.94 million	N/A	Not Optionable
IMCC IM Cannabis	340	2.23 million	2.10 million	Not Optionable

IMCC, ENLV, GDTC, and ELEV Headlines

Recent News About These Companies

IM Cannabis (NASDAQ:IMCC) Stock, Earnings Estimates, EPS, And Revenue

June 1, 2025 | benzinga.com

IM Cannabis Stock Price, Quotes and Forecasts | NASDAQ:IMCC | Benzinga

June 1, 2025 | benzinga.com

CSE Bulletin: Delist - IM Cannabis Corp. (IMCC)

May 28, 2025 | newsfilecorp.com

IM Cannabis Corp.: IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange

May 28, 2025 | finanznachrichten.de

IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange

May 28, 2025 | prnewswire.com

IM Cannabis Provides Corporate Updates

May 27, 2025 | prnewswire.com

IM Cannabis Corp. (IMCC) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

IM Cannabis Reports First Quarter Financial Results

May 15, 2025 | prnewswire.com

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

May 7, 2025 | prnewswire.com

IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

May 6, 2025 | prnewswire.com

IM Cannabis Provides Corporate Updates

April 11, 2025 | prnewswire.com

IM Cannabis 2024 net loss ticks up despite successful cost-cutting initiatives

March 31, 2025 | greenmarketreport.com

IM Cannabis Corp. (IMCC) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

IM Cannabis Reports Fourth Quarter and Full Year 2024 Financial Results

March 31, 2025 | prnewswire.com

IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ET

March 20, 2025 | prnewswire.com

IM Cannabis Announces Change of Auditors

January 17, 2025 | prnewswire.com

IM Cannabis Corp Raises Funds Amid Global Challenges

December 5, 2024 | markets.businessinsider.com

IM Cannabis Corp. (IMCC) Q3 2024 Earnings Call Transcript

November 14, 2024 | seekingalpha.com

IM Cannabis Reports Third Quarter Financial Results

November 14, 2024 | prnewswire.com

IM Cannabis to Report Third Quarter 2024 Financial Results on Thursday, November 14th at 9:00am ET

November 6, 2024 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC, ENLV, GDTC, and ELEV Company Descriptions

Elevation Oncology NASDAQ:ELEV

$0.38 +0.00 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+0.08%)

As of 04:02 PM Eastern

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Enlivex Therapeutics NASDAQ:ENLV

$0.90 -0.04 (-3.72%)

Closing price 03:58 PM Eastern

Extended Trading

$0.91 +0.01 (+0.88%)

As of 04:06 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

CytoMed Therapeutics NASDAQ:GDTC

$2.12 -0.02 (-0.84%)

Closing price 03:59 PM Eastern

Extended Trading

$2.13 +0.01 (+0.38%)

As of 04:04 PM Eastern

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

IM Cannabis NASDAQ:IMCC

$2.44 -0.18 (-6.87%)

Closing price 04:00 PM Eastern

Extended Trading

$2.49 +0.05 (+2.05%)

As of 04:37 PM Eastern

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time